9,916 results match your criteria Factor X


Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect.

Cancers (Basel) 2019 Jan 5;11(1). Epub 2019 Jan 5.

Division of Haematology and Haematology Central Laboratory, CHUV, University Hospital of Lausanne, 1011 Lausanne, Switzerland.

Cancer patients develop a hypercoagulable state with a four- to seven-fold higher thromboembolic risk compared to non-cancer patients. Thromboembolic events can precede the diagnosis of cancer, but they more often occur at diagnosis or during treatment. After malignancy itself, they represent the second cause of death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11010046DOI Listing
January 2019

Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches.

Int J Mol Sci 2018 Dec 29;20(1). Epub 2018 Dec 29.

Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.

Myc (avian myelocytomatosis viral oncogene homolog) represents one of the most sought after drug targets in cancer. Myc transcription factor is an essential regulator of cell growth, but in most cancers it is overexpressed and associated with treatment-resistance and lethal outcomes. Over 40 years of research and drug development efforts did not yield a clinically useful Myc inhibitor. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/1/120
Publisher Site
http://dx.doi.org/10.3390/ijms20010120DOI Listing
December 2018
3 Reads

Reversal of Novel Anticoagulants in Emergent Surgery and Trauma; a Comprehensive Review and Proposed Management Algorithm.

Curr Pharm Des 2018 Dec 26. Epub 2018 Dec 26.

First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens. Greece.

Non-vitamin K oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, are increasingly used for thromboembolism prevention. Contrary to older anticoagulants, such as coumadin, where antidotes existed and were broadly used in cases of emergent surgery and bleeding, antidotes for NOACs have not been developed until recently. Moreover, the monitoring of NOAC's anticoagulant effect varies across different hospital settings and the absence of a single test that can accurately predict the degree of anticoagulation achieved increases the uncertainty. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/168587/article
Publisher Site
http://dx.doi.org/10.2174/1381612825666181226150629DOI Listing
December 2018
4 Reads

Complete remission in a bleeding patient with idiopathic autoimmune factor X deficiency caused by non-neutralizing anti-factor X autoantibody.

Haemophilia 2018 Dec 20. Epub 2018 Dec 20.

Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.13675DOI Listing
December 2018

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration.

Front Vet Sci 2018 4;5:304. Epub 2018 Dec 4.

Department of Population Medicine and Diagnostic Science, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.

Horses with inflammatory and infectious disorders are often treated with injectable heparin anticoagulants to prevent thrombotic complications. In humans, a new class of direct oral acting anticoagulants (DOAC) appear as effective as heparin, while eliminating the need for daily injections. Our study in horses evaluated apixaban, a newly approved DOAC for human thromboprophylaxis targeting activated factor X (Xa). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fvets.2018.00304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288471PMC
December 2018

Synthesis, characterization, molecular docking, analgesic, antiplatelet and anticoagulant effects of dibenzylidene ketone derivatives.

Chem Cent J 2018 Dec 6;12(1):134. Epub 2018 Dec 6.

Basic Sciences Department, College of Science and Health Professions-(COSHP-J), King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

In this study dibenzylidene ketone derivatives (2E,5E)-2-(4-methoxybenzylidene)-5-(4-nitrobenzylidene) cyclopentanone (AK-1a) and (1E,4E)-4-(4-nitrobenzylidene)-1-(4-nitrophenyl) oct-1-en-3-one (AK-2a) were newly synthesized, inspired from curcuminoids natural origin. Novel scheme was used for synthesis of AK-1a and AK-2a. The synthesized compounds were characterized by spectroscopic techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13065-018-0507-1DOI Listing
December 2018
1 Read

Factor X deficiency due to a compound heterozygosis between a new mutation (Gla72Asp) in exon 2 and an already known one (Gly154Arg) in exon 5: Factor X Mar del Plata 1).

Cardiovasc Hematol Disord Drug Targets 2018 Dec 11. Epub 2018 Dec 11.

Laboratorio de Hematologia, Sanatorio Allende y Departamento de Bioquimica Clinica, Facultad de Ciencias Quimicas, Universidad Nacional de Cordoba, Cordoba. Argentina.

A compound heterozygote due to the association of a new mutation (Gla72Asp) with an already known mutation (Gly154Arg) of the FX gene is reported. The proposita is a 38 year old female who had a moderate bleeding tendency (menorrhagia, epistaxis, easy bruising). The proposita has never received substitution therapy but in the occasion of a uterine biopsy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871529X19666181212103944DOI Listing
December 2018

[Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency].

Rinsho Ketsueki 2018 ;59(11):2428-2431

Department of Blood Coagulation, Ogikubo Hospital.

A female patient in her forties exhibited no evidence of abnormal bleeding at birth. At the age of 6 years, she experienced pain in bilateral thighs and knee joints without any occasion. Accordingly, the bleeding tendency was suspected, and the coagulation profile assessment revealed prolongation of the APTT (122 s). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.59.2428DOI Listing
January 2018
1 Read

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

Cancer Manag Res 2018 8;10:5423-5431. Epub 2018 Nov 8.

Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Purpose: Although several trials have demonstrated improved progression-free survival (PFS) with first-line regimens for HER2-negative metastatic breast cancer (mBC), overall survival (OS) benefit is elusive. We calculated required sample sizes to power for OS using published data from recent mBC trials.

Patients And Methods: Randomized superiority trials of first-line chemotherapy/targeted therapy for HER2-negative mBC including >150 patients, meeting the primary efficacy objective, and published in 2000-2018 were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S177240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235000PMC
November 2018
3 Reads

Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.

J Clin Pathol 2018 Dec 5. Epub 2018 Dec 5.

Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.

Aims: Clot waveform analysis (CWA) has been reported to extend the interpretation of clotting time measurement. The parameters obtained from successive derivatives of the clotting reaction curves reflect the rates of activation of individual coagulation factors, theoretically dissecting the cascade pathway. This study aims to assess the in vitro effects of direct thrombin inhibitors (DTIs) and activated factor X (FXa) inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2018-205517DOI Listing
December 2018
1 Read

Probable Roles of Coagulation Cascade and Fibrinolysis System in the Development of Allergic Rhinitis.

Am J Rhinol Allergy 2018 Dec 6:1945892418816015. Epub 2018 Dec 6.

3 Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

Background: Dysregulation of the coagulation cascade and fibrinolysis system may play an etiologic role in many diseases. Allergic diseases such as bronchial asthma, atopic dermatitis, and conjunctivitis are also associated with fibrin accumulation caused by a change in hemostasis. However, only a few studies have dealt with the relationship between allergic rhinitis (AR) and the coagulation system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1945892418816015DOI Listing
December 2018
1 Read

Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.

Blood Coagul Fibrinolysis 2018 Nov 29. Epub 2018 Nov 29.

St. George's Haemophilia Centre, St. George's University Hospitals NHS Foundation Trust, London, UK.

: The objective was to examine the genotypic and phenotypic characteristics of individuals with hereditary factor X deficiency (FXD), a rare autosomal recessive bleeding disorder caused by mutations in the F10 gene located on chromosome 13q34-ter. To date, 149 F10 mutations have been identified as contributory to FXD. Three open-label phase 3 trials enrolled individuals with mild, moderate, or severe FXD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MBC.0000000000000787DOI Listing
November 2018
1 Read

Identification of Rfx6 target genes involved in pancreas development and insulin translation by ChIP-seq.

Biochem Biophys Res Commun 2019 Jan 30;508(2):556-562. Epub 2018 Nov 30.

Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China; Beijing Diabetes Institute, Beijing, 100730, China; Beijing Key Laboratory of Diabetes Research and Care, Beijing 100730, China. Electronic address:

Regulatory Factor X-box binding transcriptional factor 6 (Rfx6) plays an important role in the differentiation and development of pancreas in mammals. However, the direct target genes of Rfx6 to regulate this process were largely unknown. The present study aimed to investigate the function of Rfx6 on regulating pancreatic differentiation and development in a physiologically-relevant context. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2018.11.133DOI Listing
January 2019

Habu coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake venoms upon blood clotting factors.

Toxicol In Vitro 2019 Mar 22;55:62-74. Epub 2018 Nov 22.

Venom Evolution Lab, School of Biological Sciences, University of Queensland, St Lucia, QLD 4072, Australia. Electronic address:

Venom can affect any part of the body reachable via the bloodstream. Toxins which specifically act upon the coagulation cascade do so either by anticoagulant or procoagulant mechanisms. Here we investigated the coagulotoxic effects of six species within the medically important pit viper genus Protobothrops (Habu) from the Chinese mainland and Japanese islands, a genus known to produce hemorrhagic shock in envenomed patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tiv.2018.11.008DOI Listing

The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies.

Thromb Res 2019 Jan 9;173:4-11. Epub 2018 Nov 9.

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy. Electronic address:

Fusion with human serum albumin (HSA), which represents a well-established technique to extend half-life of therapeutic proteins, commonly exploits intervening peptide linkers as key components. Here, we explored the human coagulation factor X (FX) carboxyl-terminal region, previously demonstrated by us to be dispensable for secretion and coagulant activity, as a natural linker for fusion purposes. To test our hypothesis, we compared direct FX-HSA fusion with the designed FX-HSA fusion proteins mimicking the recombinant activated factor VII (rFVIIa)-HSA or factor IX (FIX)-HSA chimeras, both strongly dependent from artificial linkers. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00493848183060
Publisher Site
http://dx.doi.org/10.1016/j.thromres.2018.11.007DOI Listing
January 2019
6 Reads

Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.

J Thromb Haemost 2019 Jan 16;17(1):149-156. Epub 2018 Dec 16.

Division of Hematology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.

Essentials Protein Z (PZ) catalyzes PZ-dependent proteinase inhibitor (ZPI) inactivation of factor (F)Xa. Gene-deletion of PZ or ZPI improves coagulation in hemophilia (FVIII knockout) mice. A PZ blocking antibody enhances thrombin generation in human hemophilia plasma. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14337
Publisher Site
http://dx.doi.org/10.1111/jth.14337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322933PMC
January 2019
12 Reads

Development of a Highly Active Fluorescence-Based Detector for Yeast G Protein-Coupled Receptor Ste2p.

J Microbiol Biotechnol 2018 Oct;28(10):1589-1603

School of Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.

Twenty analogs of [Orn,D-Ala]α-factor were synthesized and assayed for their biological activities: seven analogs of [Orn,X]α-factor, seven analogs of [X,D-Ala]α-factor, five analogs of [X,X,D-Ala]α-factor, and native α-factor (X = amino acids). Their biological activities (halo, gene induction, and affinity) were measured using Y7925 and LM102 and compared with those of native α-factor (100%). G protein-coupled receptor was expressed in strain LM102 containing pESC-LEU- vector. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4014/jmb.1805.04045DOI Listing
October 2018
6 Reads

Antithrombotic medications and their impact on fibrin clot structure and function.

Authors:
A Undas M Zabczyk

J Physiol Pharmacol 2018 Aug 7;69(4). Epub 2018 Nov 7.

Institute of Cardiology, Jagiellonian University Medical College, and the John Paul II Hospital, Cracow, Poland.

Fibrin constitutes a major protein component of intravascular thrombi in all locations. Fibrin formation and its functions are essential for physiological hemostasis and the pathologic thrombosis. Formation of dense fibrin networks which are relatively resistant to lysis is observed in patients with venous or arterial thromboembolism, including myocardial infarction, ischemic stroke and venous thromboembolism. Read More

View Article

Download full-text PDF

Source
http://jpp.krakow.pl/journal/archive/08_18/pdf/10.26402/jpp.
Publisher Site
http://dx.doi.org/10.26402/jpp.2018.4.02DOI Listing
August 2018
13 Reads

[Recombinant expression and purification of spider toxin, JZTX-51 and JZTX-26, from Chilobrachys jingzhao].

Sheng Wu Gong Cheng Xue Bao 2018 Oct;34(10):1668-1678

College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha 410128, Hunan, China.

To establish a simple, quick and effective method to get a large amount of spider toxin JZTX-26 (35 aa) and JZTX-51 (27 aa) with 3 disulfide bonds each, the mature peptides coding gene fragments were constructed and fused with maltose-binding protein (MBP) tag in an Escherichia coli expression vector pMAL-p2x. The recombinant constructs pMAL-jz26 and pMAL-jz51 were transformed and cultured in E. coli TB1 and BL21 (DE3). Read More

View Article

Download full-text PDF

Source
http://doi.cnki.net/Resolution/Handler?doi=10.13345/j.cjb.17
Publisher Site
http://dx.doi.org/10.13345/j.cjb.170529DOI Listing
October 2018
10 Reads

Differential Assessment of Factor Xa Activity and Global Blood Coagulability Utilizing Novel Dielectric Coagulometry.

Sci Rep 2018 Oct 31;8(1):16129. Epub 2018 Oct 31.

Department of Biofunctional Informatics, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

An easy-to-use assessment for activated factor X (FXa) is lacking despite its pivotal role in the coagulation. Dielectric blood coagulometry (DBCM) was recently invented as a novel assessment tool for determining the whole blood coagulability by measuring the temporal change in the permittivity of blood. We previously reported that it could evaluate the global blood coagulability. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-34229-6
Publisher Site
http://dx.doi.org/10.1038/s41598-018-34229-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208345PMC
October 2018
5 Reads

Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.

Melanoma Res 2019 Feb;29(1):99-101

Division of Pediatric Hematology-Oncology, Oncology Institute, Istanbul University.

Malignant melanoma is very rare in childhood. The approach to diagnosis and treatment in children has been adopted from adult guidelines. Vemurafenib is indicated in adults with BRAF V600 mutation-positive stage IIIc/IV melanoma and causes cutaneous adverse events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000537DOI Listing
February 2019
2 Reads

Hypertension and obesity moderate the relationship between β-amyloid and cognitive decline in midlife.

Alzheimers Dement 2018 Oct 25. Epub 2018 Oct 25.

Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.

Background: This study tested if central obesity, hypertension, or depressive symptoms moderated the relationship between β-amyloid (Aβ) and longitudinal cognitive performance in late middle-aged adults enriched for Alzheimer's disease (AD) risk.

Methods: Participants (n = 207; ages = 40-70 years; 73% parental AD) in the Wisconsin Registry for Alzheimer's Prevention study completed 3+ neuropsychological evaluations and a [C]PiB positron emission tomography scan or lumbar puncture. Linear mixed-effects regression models tested interactions of risk factor × Aβ × visit age on longitudinal Verbal Learning & Memory and Speed & Flexibility factor scores. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15525260183355
Publisher Site
http://dx.doi.org/10.1016/j.jalz.2018.09.008DOI Listing
October 2018
5 Reads

The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.

Ther Adv Hematol 2018 Oct 10;9(10):319-334. Epub 2018 Oct 10.

Division of Pediatric Hematology/Oncology, Carmen and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, 3901 Beuabien St, Detroit, MI 48201, USA.

Hemophilia A, characterized by impaired or absent expression of factor VIII, has long been managed direct factor replacement. Functionally, factor VIII acts as a cofactor for factor IXa and allows activation of factor X, which, in combination with factor V, generates thrombin. Bispecific antibodies such as emicizumab are recombinant, monoclonal antibodies capable of recognizing and binding to two distinct antigenic targets simultaneously; emicizumab binds factors IXa and X, resulting in spatial approximation and activation of factor X, thereby mimicking the actions of factor VIII. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620718799997DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187429PMC
October 2018
1 Read

The transcription factor TpRfx1 is an essential regulator of amylase and cellulase gene expression in .

Biotechnol Biofuels 2018 8;11:276. Epub 2018 Oct 8.

State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, Guangxi Research Center for Microbial and Enzyme Engineering Technology, College of Life Science and Technology, Guangxi University, 100 Daxue Road, Nanning, 530004 Guangxi People's Republic of China.

Background: Perfect and low cost of fungal amylolytic and cellulolytic enzymes are prerequisite for the industrialization of plant biomass biorefinergy to biofuels. Genetic engineering of fungal strains based on regulatory network of transcriptional factors (TFs) and their targets is an efficient strategy to achieve the above described aim. produces integrative amylolytic and cellulolytic enzymes; however, the regulatory mechanism associated with the expression of amylase and cellulase genes in remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13068-018-1276-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174557PMC
October 2018
8 Reads

Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.

Anesth Analg 2018 Oct 12. Epub 2018 Oct 12.

Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland.

Background: Recombinant activated factor VII (rFVIIa) concentrate reduces allogeneic blood transfusions, but it may increase thromboembolic complications in complex cardiac surgery. The mixture of activated factor VII (FVIIa) and factor X (FX) (FVIIa/FX) (FVIIa:FX = 1:10) is a novel bypassing agent for hemophilia patients. We hypothesized that the combination of FX and FVIIa could improve thrombin generation (TG) in acquired multifactorial coagulation defects such as seen in cardiac surgery and conducted in vitro evaluation of FVIIa/FX in parallel with other coagulation factor concentrates using in vitro and in vivo diluted plasma samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1213/ANE.0000000000003858DOI Listing
October 2018
8 Reads

Protease-activated receptors are potential regulators in the development of arterial endofibrosis in high-performance athletes.

J Vasc Surg 2018 Oct 9. Epub 2018 Oct 9.

Laboratory for Clinical Thrombosis and Hemostasis, Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands.

Objective: High-performance athletes can develop symptomatic arterial flow restriction during exercise caused by endofibrosis. The pathogenesis is poorly understood; however, coagulation enzymes, such as tissue factor (TF) and coagulation factor Xa, might contribute to the fibrotic process, which is mainly regulated through activation of protease-activated receptors (PARs). Therefore, the aim of this explorative study was to evaluate the presence of coagulation factors and PARs in endofibrotic tissue, which might be indicative of their potential role in the natural development of endofibrosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S07415214183163
Publisher Site
http://dx.doi.org/10.1016/j.jvs.2018.05.220DOI Listing
October 2018
9 Reads

Coagulotoxicity of (Lancehead Pit-Vipers) Venoms from Brazil: Differential Biochemistry and Antivenom Efficacy Resulting from Prey-Driven Venom Variation.

Toxins (Basel) 2018 Oct 11;10(10). Epub 2018 Oct 11.

Venom Evolution Lab, School of Biological Sciences, University of Queensland, St. Lucia, QLD 4072, Australia.

Lancehead pit-vipers ( genus) are an extremely diverse and medically important group responsible for the greatest number of snakebite envenomations and deaths in South America. (common lancehead), responsible for majority of snakebites and related deaths within the Brazilian Amazon, is a highly adaptable and widely distributed species, whose venom variability has been related to several factors, including geographical distribution and habitat type. This study examined venoms from four populations (Belterra and Santarém, PA; Pres. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6651/10/10/411
Publisher Site
http://dx.doi.org/10.3390/toxins10100411DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215258PMC
October 2018
2 Reads

The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions.

J Biomed Sci 2018 Oct 4;25(1):71. Epub 2018 Oct 4.

Institute of Biomedical Sciences, Academia Sinica, 128 Sec. 2, Academia Rd. Nankang, Taipei, 115, Taiwan, Republic of China.

Psychiatric disorders (such as bipolar disorder, depression, and schizophrenia) affect the lives of millions of individuals worldwide. Despite the tremendous efforts devoted to various types of psychiatric studies and rapidly accumulating genetic information, the molecular mechanisms underlying psychiatric disorder development remain elusive. Among the genes that have been implicated in schizophrenia and other mental disorders, disrupted in schizophrenia 1 (DISC1) and glycogen synthase kinase 3 (GSK3) have been intensively investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12929-018-0473-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171312PMC
October 2018
1 Read

Acquired factor V inhibitor-related severe bleeding due to unformed prothrombinase complex.

Thromb Res 2018 11 20;171:81-83. Epub 2018 Sep 20.

Nagahama Institute of Bio-Science and Technology, Shiga, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2018.09.052DOI Listing
November 2018
20 Reads

Common Conditions Requiring Long-Term Anticoagulation in Neurosurgical Patients.

Neurosurg Clin N Am 2018 Oct;29(4):529-535

Department of Neurosurgery, Stanford University Medical Center, 300 Pasteur Drive Room R211, MC 5327, Stanford, CA 94305, USA. Electronic address:

Long-term anticoagulant therapy prevents thrombosis. Management of neurosurgical patients with conditions such as atrial fibrillation, mechanical heart valves, and other prothrombotic states necessitates application of a strategy to mitigate hemorrhagic complications of anticoagulation. Development of direct oral anticoagulants, which include the direct thrombin and factor X inhibitors, yields new considerations to be had, in particular, the introduction of reversal agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nec.2018.06.009DOI Listing
October 2018

Anticoagulation in atrial fibrillation with factor X deficiency-A management dilemma.

Clin Case Rep 2018 Sep 22;6(9):1781-1785. Epub 2018 Jul 22.

Associates in Hematology and Oncology, P.C. Crozer Regional Cancer Center Upland Pennsylvania.

Factor X (FX) deficiency is a rare bleeding disorder. There is currently no clear guideline or recommendation for the appropriate selection of anticoagulation and management of patients with FX deficiency who require anticoagulation. We shared our experience in managing such patient, and we further discussed other possible treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1731DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132141PMC
September 2018
1 Read

Caffeine and Sprint Cycling Performance: Effects of Torque Factor and Sprint Duration.

Int J Sports Physiol Perform 2018 Sep 11:1-19. Epub 2018 Sep 11.

a School of Sport, Health, and Applied Sciences, St Mary's University, Strawberry Hill, Twickenham, UK.

Purpose: The aim of this study was to investigate the influence of torque factor and sprint duration on the effects of caffeine on sprint cycling performance.

Methods: Using a counterbalanced, randomized, double-blind, placebo-controlled design, 13 men completed nine trials. In Trial 1, participants completed a series of 6 s sprints at increasing torque factors, to determine the torque factor, for each individual, which elicited the highest (T) peak power output (PPO). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1123/ijspp.2018-0458DOI Listing
September 2018
1 Read

Preeclampsia and the 20th century: "Le siècle des Lumières".

Pregnancy Hypertens 2018 Jul 30;13:107-109. Epub 2018 May 30.

Department of Epidemiology, School of Public Health, West Virginia University, United States.

The authors delineate seven quantum leap forward and, or revolutions having occurred during the 20th century in the understanding of the physiopathology of preeclampsia. First the discovery of the inflatable arm band permitting to measure blood pressure in 1896. Second, the discovery that eclamptic (convulsions), and later "pre"eclamptic (proteinuria) women presented hypertension in 1897 and confirmed in 1903, discovery of the hypertensive disorders of pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.preghy.2018.05.013DOI Listing
July 2018
1 Read

Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity.

J Thromb Haemost 2018 Nov 9;16(11):2276-2288. Epub 2018 Oct 9.

Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.

Essentials Activated clotting factor X (FXa) acquires fibrinolytic cofactor function after cleavage by plasmin. FXa-mediated plasma fibrinolysis is enabled by active site modification blocking a second cleavage. FXa-directed oral anticoagulants (DOACs) alter FXa cleavage by plasmin. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jth.14281
Publisher Site
http://dx.doi.org/10.1111/jth.14281DOI Listing
November 2018
10 Reads

Translin modulates mesenchymal cell proliferation and differentiation in mice.

Biochem Biophys Res Commun 2018 Sep 29;504(1):115-122. Epub 2018 Aug 29.

Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, Kobe, 654-0142, Japan; Consolidated Research Institute for Advanced Science and Medical Care, Waseda University, Tokyo, 169-8555, Japan. Electronic address:

Translin, a highly conserved DNA/RNA binding protein that forms a hetero-octamer together with Translin-associated factor X (TRAX), possesses a broad variety of functions, including RNA processing and DNA repair. Recent studies have reported that Translin is involved in mesenchymal cell physiology. Thus, here we analyzed the intrinsic role of Translin in mesenchymal cell proliferation and differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2018.08.141DOI Listing
September 2018
2 Reads

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

N Engl J Med 2018 08;379(9):811-822

From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universitätsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann-La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan (M.E.M.); the Hematology Department, Hospital Universitario La Paz, Autónoma University, Madrid (V.J.-Y.); the Department of Hematology and Medical Oncology, Emory School of Medicine, Atlanta (C.K.); Children's Hospital of Michigan, Detroit (M.U.C.); Instituto Costarricense de Investigaciones Científicas, San José, Costa Rica (W.B.); the Department of Pediatrics, Nara Medical University, Kashihara, Japan (M.S.); and the Washington Center for Bleeding Disorders at Bloodworks Northwest, Seattle (R.K.-J.).

Background: Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. In a phase 3, multicenter trial, we investigated its use as prophylaxis in persons who have hemophilia A without factor VIII inhibitors.

Methods: We randomly assigned, in a 2:2:1 ratio, participants 12 years of age or older who had been receiving episodic treatment with factor VIII to receive a subcutaneous maintenance dose of emicizumab of 1. Read More

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1803550
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1803550DOI Listing
August 2018
15 Reads

Congenital coagulation factor X deficiency: Genetic analysis of five patients and functional characterization of mutant factor X proteins.

Haemophilia 2018 Sep 28;24(5):774-785. Epub 2018 Aug 28.

Department of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.

Congenital factor X (FX) deficiency is a rare bleeding disorder that is inherited as an autosomal recessive trait. In this study, a genetic analysis of the FX gene was performed in five families with this disorder. Four heterozygous mutations [p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.13606DOI Listing
September 2018
1 Read

Calibration of the 7th British Working Standard for factors II, IX and X, concentrate.

Biologicals 2018 Nov 24;56:63-66. Epub 2018 Aug 24.

Haemostasis Section, Biotherapeutics Group, National Institute of Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK.

Seven laboratories from 5 different countries participated in the calibration of the 7th British Working Standard (BWS) for blood coagulation factors II, IX and X. The candidate, 15/182, was assayed for Factors II and X potencies against the 4th International Standard (IS) for Factors II and X, Concentrate (11/126) and for Factor IX potency against the 5th IS for Factor IX, Concentrate (14/148). Intra-laboratory GCVs for all 3 factors were less than 10%, with the majority less than 5%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biologicals.2018.08.007DOI Listing
November 2018
2 Reads

The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.

J Biol Chem 2018 Oct 23;293(40):15691-15705. Epub 2018 Aug 23.

From the National Cancer Tissue Biobank, Laboratory of Molecular Cell Biology and

is a proto-oncogene controlling expression of multiple genes involved in cell growth and differentiation. Although the functional role of c-Myc as a transcriptional regulator has been intensively studied, targeting this protein in cancer remains a challenge. Here, we report a trimodal regulation of c-Myc function by the Ras effector, Ras-association domain family member 7 (RASSF7), a nonenzymatic protein modulating protein-protein interactions to regulate cell proliferation. Read More

View Article

Download full-text PDF

Source
http://www.jbc.org/lookup/doi/10.1074/jbc.RA118.004452
Publisher Site
http://dx.doi.org/10.1074/jbc.RA118.004452DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177588PMC
October 2018
18 Reads

Differential heme-mediated modulation of Deinagkistrodon, Dispholidus, Protobothrops and Pseudonaja hemotoxic venom activity in human plasma.

Biometals 2018 Dec 21;31(6):951-959. Epub 2018 Aug 21.

Mtoxins, 1111 Washington Ave, Oshkosh, WI, 54901, USA.

Envenomation by vipers with hemotoxic enzymes continues to be a worldwide source of morbidity and mortality. The present work examined the effects of exposure of venom enzymes to carbon monoxide and O-phenylhydroxylamine, agents that modulate the biometal heme, by forming carboxyheme and metheme, respectively. Four venoms obtained from medically important, diverse snake venom found in Africa, Asia and Australia were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10534-018-0137-zDOI Listing
December 2018
2 Reads

Auto-fatty acylation of transcription factor RFX3 regulates ciliogenesis.

Proc Natl Acad Sci U S A 2018 09 20;115(36):E8403-E8412. Epub 2018 Aug 20.

Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129;

Defects in cilia have been associated with an expanding human disease spectrum known as ciliopathies. Regulatory Factor X 3 (RFX3) is one of the major transcription factors required for ciliogenesis and cilia functions. In addition, RFX3 regulates pancreatic islet cell differentiation and mature β-cell functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1800949115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130365PMC
September 2018
12 Reads

Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting.

Mol Cancer Ther 2018 Nov 20;17(11):2412-2426. Epub 2018 Aug 20.

Iconic Therapeutics, South San Francisco, California.

The primary function of tissue factor (TF) resides in the vasculature as a cofactor of blood clotting; however, multiple solid tumors aberrantly express this transmembrane receptor on the cell surface. Here, we developed anti-TF antibody-drug conjugates (ADC) that did not interfere with the coagulation cascade and benchmarked them against previously developed anti-TF ADCs. After screening an affinity-matured antibody panel of diverse paratopes and affinities, we identified one primary paratope family that did not inhibit conversion of Factor X (FX) to activated Factor X (FXa) and did not affect conversion of prothrombin to thrombin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-0471DOI Listing
November 2018
4 Reads
5.683 Impact Factor

Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIX.

Virus Res 2018 09 17;257:40-51. Epub 2018 Aug 17.

Department of Fundamental and Applied Neurobiology, V.P. Serbsky Federal Medical Research Center of Psychiatry and Narcology, The Ministry of Health of the Russian Federation, Kropotkinsky lane 23, 119034 Moscow, Russia; Department of Medical Nanobiotechnologies, Medico-Biological Faculty, N.I. Pirogov Russian National Research Medical University, The Ministry of Health of the Russian Federation, Ostrovitianov str. 1, 117997 Moscow, Russia. Electronic address:

The cellular internalization (infection of cells) of adenovirus 5 (Ad5) is mediated by the initial attachment of the globular knob domain of the capsid fiber protein to the cell surface coxsackievirus and adenovirus receptor (CAR), then followed by the interaction of the virus penton base proteins with cellular integrins. In tumors, there is a substantial intra- and intertumoral variability in CAR expression. The CAR-negative cells generally exhibit very low infectability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.virusres.2018.08.012DOI Listing
September 2018
27 Reads

High frequency of anti-protein Z antibodies in patients with anticardiolipin antibodies.

Immunobiology 2018 Dec 6;223(12):772-776. Epub 2018 Aug 6.

Department of Clinical Biology & INSERM UMRS-1176, Foch Hospital, Suresnes, France. Electronic address:

Protein Z (PZ) is a vitamin K-dependent protein involved in the down-regulation of coagulation by forming a complex with the protein Z-dependent protease inhibitor. The complex inhibits the activated factor X on phospholipid surface. Presence of anti-PZ (aPZ) antibodies was first described in women with pathological pregnancies but the significance of aPZ antibodies in other pathological situations was poorly studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.imbio.2018.08.001DOI Listing
December 2018
1 Read

Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.

Acta Haematol 2018 16;140(1):46-50. Epub 2018 Aug 16.

A 62-year-old female presenting with anemia and extensive hemorrhages is reported. Coagulation tests showed significantly prolonged prothrombin time (PT) and activated partial thromboplastin time. Decreased levels of clotting factor X activity were determined (5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491545DOI Listing
August 2018
3 Reads
0.994 Impact Factor

Exendin-4 protects INS-1 cells against palmitate-induced apoptosis through the IRE1α-Xbp1 signaling pathway.

Exp Ther Med 2018 Aug 30;16(2):1029-1035. Epub 2018 May 30.

Department of Orthopedic Sports Medicine, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China.

The anti-apoptotic effect of the incretin analog, exendin-4 (EX-4) on pancreatic β cells is mediated via the activation of protein kinase B (Akt) signaling, and its effect is partly produced through the inhibition of endoplasmic reticulum (ER) stress. However, the molecular mechanisms that underlie the effect of EX-4 on the suppression of ER stress and the upregulation of Akt signaling are poorly understood. Inositol-requiring enzyme 1 (IRE1), a member of the ER-localized transmembrane protein family, activates its downstream transcription factor X-box binding protein 1 (XBP1) to mediate a key part of the cellular unfolded protein response in order to cope with ER stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.6240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090425PMC
August 2018
1 Read

[Genotypic and phenotypic analysis of a case with inherited coagulation factor X deficiency].

Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2018 Aug;35(4):544-547

Department of Laboratory Medicine, the Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.

Objective: To explore the correlation between F10 gene mutation and its phenotype in a Chinese pedigree affected with FX deficiency.

Methods: Prothrombin time(PT), activated partial thromboplastin time(APTT), fibrinogen, FII activity(FII:C), FVII activity(FVII:C), FIX activity (FIX:C), FX activity(FX:C) were determined with a one-stage clotting assay. The FX antigen(FX:Ag) was detected with an enzyme linked immunosorbent assay(ELISA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.1003-9406.2018.04.019DOI Listing
August 2018
9 Reads

Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis.

JCI Insight 2018 Aug 9;3(15). Epub 2018 Aug 9.

Department of Surgery, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA.

Despite advances in antithrombotic therapy, the risk of recurrent coronary/cerebrovascular ischemia or venous thromboembolism remains high. Dual pathway antithrombotic blockade, using both antiplatelet and anticoagulant therapy, offers the promise of improved thrombotic protection; however, widespread adoption remains tempered by substantial risk of major bleeding. Here, we report a dual pathway therapeutic capable of site-specific targeting to activated platelets and therapeutic enrichment at the site of thrombus growth to allow reduced dosing without compromised antithrombotic efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.99329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129120PMC
August 2018
1 Read

A patient with a germline mutation presenting with an isolated pituitary macroprolactinoma.

Endocrinol Diabetes Metab Case Rep 2018 21;2018. Epub 2018 Jul 21.

Endocrinology, Imperial College Healthcare NHS Trust, London, UK.

Symptomatic pituitary adenomas occur with a prevalence of approximately 0.1% in the general population. It is estimated that 5% of pituitary adenomas occur in a familial setting, either in isolated or syndromic form. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EDM-18-0078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063986PMC
July 2018
11 Reads